

Global SCD/?-Thal Gene Therapy Outlook 2025–2033: Size, Trends, Key Players Market - 2026-2033

<https://marketpublishers.com/r/G4DC473BBFE1EN.html>

Date: November 2025

Pages: 0

Price: US\$ 3,400.00 (Single User License)

ID: G4DC473BBFE1EN

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Drug
- 2.4. Snippet by Route of Administration
- 2.5. Snippet by Distribution Channel
- 2.6. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising in Clinical Trials for Gene Therapy
 - 3.1.1.2. Rising Prevalence + High Unmet Need
 - 3.1.2. Restraints
 - 3.1.2.1. Very High Cost of Gene Therapies and Access Challenges
 - 3.1.2.2. Disease-Specific and Geographic Adoption Challenges
 - 3.1.3. Opportunity
 - 3.1.3.1. Broader Indication Expansion & Earlier Intervention

3.1.3.2. New Delivery Platforms and Next-Generation Gene Therapies

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. South America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
 - 4.4.1. Bargaining Power of Suppliers
 - 4.4.2. Bargaining Power of Buyers
 - 4.4.3. Threat of Substitutes
 - 4.4.4. Threat of New Entrants
 - 4.4.5. Competitive Rivalry
- 4.5. Patent Analysis
 - 4.5.1. Patent Expiry and Exclusivity
 - 4.5.2. Key Patent Holders
 - 4.5.3. Patent Litigations
 - 4.5.4. Licensing Opportunities
- 4.6. Unmet Needs and Gaps
- 4.7. Recommended Strategies for Market Entry and Expansion
- 4.8. Pricing Analysis and Price Dynamics
 - 4.8.1. Price Benchmarking vs. Competitors
 - 4.8.2. Reimbursement Landscape
 - 4.8.3. Pricing Trends by Region or Segment
 - 4.8.4. Value-Based Pricing Opportunities
- 4.9. SWOT Analysis
 - 4.9.1. Strengths: Internal Advantages
 - 4.9.2. Weaknesses: Internal Limitations
 - 4.9.3. Opportunities: External Growth Possibilities
 - 4.9.4. Threats: External Challenges
- 4.10. Supply Chain Analysis

- 4.10.1. Raw Material Sourcing
- 4.10.2. Manufacturing Locations
- 4.10.3. Distribution Channels
- 4.10.4. Logistics and Transportation
- 4.10.5. Supplier Risk Assessment

5. SICKLE CELL DISEASE (SCD) AND β -THALASSEMIA GENE THERAPY MARKET, BY DRUG

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
 - 5.1.2. Market Attractiveness Index, By Drug
- 5.2. ZYNTGLO*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. CASGEVY
- 5.4. LYFGENIA

6. SICKLE CELL DISEASE (SCD) AND β -THALASSEMIA GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 6.1.2. Market Attractiveness Index, By Route of Administration
- 6.2. Intravenous*

7. SICKLE CELL DISEASE (SCD) AND β -THALASSEMIA GENE THERAPY MARKET, BY DISTRIBUTION CHANNEL

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 7.1.2. Market Attractiveness Index, By Distribution Channel
- 7.2. Hospital Pharmacies*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Retail Pharmacies

8. SICKLE CELL DISEASE (SCD) AND β -THALASSEMIA GENE THERAPY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

8.1.2. Market Attractiveness Index, By Region

8.2. North America

8.2.1. Introduction

8.2.2. Key Region-Specific Dynamics

8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.2.6.1. U.S.

8.2.6.2. Canada

8.2.6.3. Mexico

8.3. Europe

8.3.1. Introduction

8.3.2. Key Region-Specific Dynamics

8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.3.6.1. Germany

8.3.6.2. UK

8.3.6.3. France

8.3.6.4. Spain

8.3.6.5. Italy

8.3.6.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. Introduction

8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.4.6.1. China

8.4.6.2. India

8.4.6.3. Japan

8.4.6.4. South Korea

8.4.6.5. Rest of Asia-Pacific

8.5. South America

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.5.6.1. Brazil

8.5.6.2. Argentina

8.5.6.3. Rest of South America

8.6. Middle East and Africa

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

9.1. Competitive Overview and Key Market Players

9.2. Market Share Analysis and Positioning Matrix

9.3. Strategic Partnerships, Mergers & Acquisitions

9.4. Key Developments in Product Portfolios and Innovations

9.5. Company Benchmarking

10. COMPANY PROFILES

10.1. Top Players

10.1.1. Bluebird bio, Inc.*

10.1.1.1. Company Overview

10.1.1.2. Product Portfolio

10.1.1.2.1. Product Description

10.1.1.2.2. Product Key Performance Indicators (KPIs)

10.1.1.3. Financial Overview

- 10.1.1.3.1. Company Revenue
- 10.1.1.3.2. Geographical Revenue Shares
- 10.1.1.3.3. Revenue Forecasts
- 10.1.1.4. Key Developments
 - 10.1.1.4.1. Mergers & Acquisitions
 - 10.1.1.4.2. Key Product Development Activities
 - 10.1.1.4.3. Regulatory Approvals, etc.
 - 10.1.1.4.4. SWOT Analysis
- 10.2. CRISPR Therapeutics
 - 10.2.1. Emerging Players
 - 10.2.1.1. Sangamo Therapeutics, Inc.
 - 10.2.1.2. Editas Medicine
 - 10.2.1.3. Beam Therapeutics.
 - 10.2.1.4. Editas Medicine
 - 10.2.1.5. CorrectSequence Therapeutics Co., Ltd. (LIST NOT EXHAUSTIVE)

11. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 11.1. Data Collection Methods
- 11.2. Data Triangulation
- 11.3. Forecasting Techniques
- 11.4. Data Verification and Validation

12. APPENDIX

- 12.1. About Us and Services
- 12.2. Contact Us

I would like to order

Product name: Global SCD/?-Thal Gene Therapy Outlook 2025–2033: Size, Trends, Key Players Market - 2026-2033

Product link: <https://marketpublishers.com/r/G4DC473BBFE1EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4DC473BBFE1EN.html>